New Risk • Mar 08
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.6m free cash flow). Earnings have declined by 47% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (AU$7.56m market cap, or US$5.31m). New Risk • Mar 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$2.6m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.6m free cash flow). Earnings have declined by 47% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (AU$6.85m market cap, or US$4.88m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding). お知らせ • Oct 24
Invion Limited, Annual General Meeting, Nov 26, 2025 Invion Limited, Annual General Meeting, Nov 26, 2025. お知らせ • Oct 10
Invion Limited announced that it expects to receive AUD 0.782254 million in funding Invion Limited announced private placement to issue 71,114 Zero Coupon Unsecured Convertible Notes at a price of AUD 11 each for aggregate gross proceeds of AUD 782,254 on October 10, 2025. The Notes will have a maturity date of February 28, 2026 and a conversion price of AUD 0.11. The company will pay y the lead manager, Blue Ocean, a management fee equivalent to 3% of the total proceeds raised under the Offer and a 3% selling fee calculated on the total proceeds raised under the Offer, less Chairman’s list investors. The transaction is expected to close on or about October 16, 2025. The transaction will include participation from Summit Biotech Fund and other sophisticated investors. New Risk • Aug 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$3.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.0m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 46% per year over the past 5 years. Revenue is less than US$1m (AU$3.0k revenue, or US$2.0k). Market cap is less than US$10m (AU$11.1m market cap, or US$7.25m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding). New Risk • Aug 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 36% per year over the past 5 years. Revenue is less than US$1m (AU$1.5m revenue, or US$951k). Market cap is less than US$10m (AU$12.4m market cap, or US$8.04m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding). お知らせ • Jun 13
Invion Limited has announced a Derivatives Offering in the amount of AUD 1 million. Invion Limited has announced a Derivatives Offering in the amount of AUD 1 million.
Security Name: Loyalty Option
Security Type: Equity Option
Securities Offered: 66,666,667
Price\Range: AUD 0.015
Transaction Features: Rights Offering New Risk • Jun 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Revenue is less than US$1m (AU$1.5m revenue, or US$946k). Market cap is less than US$10m (AU$10.6m market cap, or US$6.83m). New Risk • May 27
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 36% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m (AU$1.5m revenue, or US$945k). Market cap is less than US$10m (AU$7.37m market cap, or US$4.75m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). New Risk • Mar 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 36% per year over the past 5 years. Revenue is less than US$1m (AU$1.5m revenue, or US$921k). Market cap is less than US$10m (AU$8.90m market cap, or US$5.59m). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). お知らせ • Mar 04
Invion Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million. Invion Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 7,250,269
Price\Range: AUD 0.14
Discount Per Security: AUD 0.0084
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 7,035,447
Price\Range: AUD 0.14
Discount Per Security: AUD 0.0084
Transaction Features: Subsequent Direct Listing New Risk • Mar 01
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: AU$1.4m (US$887k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$2.8m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 36% per year over the past 5 years. Revenue is less than US$1m (AU$1.4m revenue, or US$887k). Market cap is less than US$10m (AU$9.85m market cap, or US$6.11m). New Risk • Jan 20
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.5m (US$9.59m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.3m free cash flow). Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (AU$15.5m market cap, or US$9.59m). Minor Risk Revenue is less than US$5m (AU$3.7m revenue, or US$2.3m). お知らせ • Oct 28
Invion Limited Announces Change of Company Secretary Invion Limited announced the appointment of Ms. Melanie Leydin as Company Secretary, effective immediately. Mr. Phan will resign as Company Secretary of Invion, effective immediately. Invion further advised that, in accordance with Listing Rule 12.6 and with immediate effect, Ms. Leydin is the person responsible for communications with ASX in relation to Listing Rule matters. お知らせ • Oct 15
Invion Limited, Annual General Meeting, Nov 14, 2024 Invion Limited, Annual General Meeting, Nov 14, 2024. Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0 in FY 2023) Full year 2024 results: AU$0.001 loss per share (further deteriorated from AU$0 in FY 2023). Revenue: AU$3.74m (down 8.8% from FY 2023). Net loss: AU$5.63m (loss widened 249% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. New Risk • Aug 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$13.3m (US$8.93m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.1m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 0.9% per year over the past 5 years. Market cap is less than US$10m (AU$13.3m market cap, or US$8.93m). Minor Risks Shareholders have been diluted in the past year (3.4% increase in shares outstanding). Revenue is less than US$5m (AU$4.4m revenue, or US$3.0m). New Risk • Aug 14
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$6.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$6.1m free cash flow). Share price has been highly volatile over the past 3 months (28% average weekly change). Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (3.4% increase in shares outstanding). Revenue is less than US$5m (AU$4.4m revenue, or US$2.9m). Market cap is less than US$100m (AU$19.9m market cap, or US$13.2m). お知らせ • Jul 31
Invion Limited Announces Change of Company Secretary Invion Limited announced the appointment of Mr. Tai Phan as Company Secretary, effective immediately. Mr. Phan has over 20 years' experience as a lawyer, Company Secretary, and corporate governance and compliance professional. He has worked directly with Boards and executive management of several ASX-listed entities (i.e. Zip Co Limited, Westpac Banking Corp, HT&E Limited, and Yancoal Australia Ltd) and numerous unlisted companies across multiple industries. He has experience in the IPO listing process for the ASX, has been appointed an external consultant for AUSTRAC and as the Head of AsiaPac Compliance (for Travelex and Munich Re). Ms Claire Newstead-Sinclair will resign as Company Secretary of Invion, effective immediately. New Risk • Jul 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.8% increase in shares outstanding). Revenue is less than US$5m (AU$4.4m revenue, or US$3.0m). Market cap is less than US$100m (AU$26.4m market cap, or US$17.9m). お知らせ • Oct 30
Invion Limited, Annual General Meeting, Nov 29, 2023 Invion Limited, Annual General Meeting, Nov 29, 2023, at 13:00 AUS Eastern Standard Time. Agenda: To consider Adoption of Remuneration Report; to consider Re-election of Mr. Alistair Bennallack as a Director of the Company; and to consider Approval of 10% Placement Facility. Reported Earnings • Oct 01
Full year 2023 earnings released: EPS: AU$0 (vs AU$0 in FY 2022) Full year 2023 results: EPS: AU$0 (in line with FY 2022). Revenue: AU$4.10m (up 25% from FY 2022). Net loss: AU$1.61m (loss narrowed 28% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 18% per year. Reported Earnings • Sep 01
Full year 2023 earnings released: EPS: AU$0 (vs AU$0 in FY 2022) Full year 2023 results: EPS: AU$0 (in line with FY 2022). Revenue: AU$4.14m (up 26% from FY 2022). Net loss: AU$1.61m (loss narrowed 28% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 26% per year whereas the company’s share price has fallen by 23% per year. New Risk • Aug 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (28% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (AU$3.9m revenue, or US$2.5m). Market cap is less than US$100m (AU$32.1m market cap, or US$20.6m). Reported Earnings • Feb 24
First half 2023 earnings released: EPS: AU$0 (vs AU$0 in 1H 2022) First half 2023 results: EPS: AU$0 (in line with 1H 2022). Revenue: AU$1.95m (up 50% from 1H 2022). Net loss: AU$830.7k (loss narrowed 21% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 11% per year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Alistair Bennallack was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. お知らせ • Oct 28
Invion Limited Announces Vitro Test Results on Photosoft Invion Limited announced the first in vitro test results on Photosoft that were undertaken by the Australian Centre for Antimicrobial Resistance Ecology (ACARE), University of Adelaide, in partnership with Invion. The studies tested activity of PhotosoftTM compounds across a range of pathogens and found the following: Five of the seven PhotosoftTM compounds tested against two strains of methicillin-resistant Staphylococcus aureus (MRSA) bacteria displayed antimicrobial activity. MRSA is described as a "superbug" as the bacteria is resistant to several antibiotics and is difficult to treat. The World Health Organization (WHO) calls antimicrobial resistance "one of the top 10 global public health threats facing humanity" and cites the misuse and overuse of antibiotics as the main drivers in the development of drug-resistant pathogens1. ACARE also found that the same five compounds mentioned above were very active against two Candida albicans strains (a type of yeast that causes fungal infections) strains on exposure to a specific wavelength (660nm) of light. Candida albicans normally lives on skin and in bodies without problem. But it can cause vaginal candidiasis and infections in the bloodstream and internal organs if it grows out of control or enters deep into the body. The global yeast infection treatment market is forecast to grow at a compound annual growth rate of 6.1% to hit USD 6.23 billion by 2029 and Candida accounts for the large pathogen segment in this market. Further, the PhotosoftTM compounds tested showed potential to be used against Escherichia coli. E. coli bacteria, which can be found in the intestines of healthy people and are mostly harmless. But some pathogenic strains can cause severe diarrhoea whilst others cause disease outside the gut such as wound and urinary tract infections as well as blood poisoning. お知らせ • Oct 25
Invion Limited Announces the Positive Screening Results from in Vitro Studies of PhotosoftTM on the Inhibition of the Dengue Virus Invion Limited announce the positive screening results from in vitro studies of PhotosoftTM on the inhibition of the Dengue virus. The tests, which were done on ten PhotosoftTM photodynamic compounds at eight concentrations, found that eight of the 10 compounds displayed antiviral activity against the Dengue virus after exposure to a specific light wavelength (660nm). The EC50 (half maximal effective concentration) values of the eight PhotosoftTM compounds that showed antiviral activity ranged between 11.1nM and 539nM. These values were significantly below that of Monensin (1031nM), an antibiotic with known activity against Dengue virus was used as a control. None of the compounds were antiviral in the absence ofthis light source. お知らせ • Oct 14
Invion Limited, Annual General Meeting, Nov 17, 2022 Invion Limited, Annual General Meeting, Nov 17, 2022, at 12:00 AUS Eastern Standard Time. Agenda: To receive and consider the financial report of the Company and the related reports of the Directors (including the Remuneration Report) and auditors for the period ended 30 June 2022; to adopt Remuneration Report; to consider board changes; to approve amendments to the Constitution; and to consider other matters. お知らせ • Sep 16
Invion Limited Announces INV043 Effective Against Anal Cancer Squamous Cell Carcinomas in Vitro Invion Limited announced the first set of laboratory results from the Peter MacCallum Cancer Centre (Peter Mac) testing INV043 on squamous cell carcinoma (SCC) cell lines, which are linked to anal cancers. The in vitro tests showed that photoactivated INV043 was effective against the six SCC cell lines that cover the spectrum found in anal cancers. The overall results from this study are consistent with the promising outcomes achieved at the Hudson Institute of Medical Research (Hudson Institute) on other cancer types, including triple negative breast cancer. INV043 is Invion's lead drug candidate and represents the next generation of photodynamic therapy that aims to treat multiple types of cancers. The core purpose of these studies was to assess the relative cytotoxicity of light activated INV043 of human anal SSC cell lines. These data are a prelude to planned in vivo studies. This was done by: Comparing the phototoxicity of a sentinel cell line used in both Hudson Institute (HIMR) and Peter Mac (PMCC) research laboratories, namely immortalised human embryonic kidney cells (HEK) Testing phototoxicity of human HPV+ve and ve anal SCC cell lines Testing phototoxicity of a unique mouse anal SCC model developed at the PMCC which comes in two forms: parental line and one with human HPV E6 and E7 oncoproteins. This second line is a faithful mouse version of human HPV+ve anal cancer. お知らせ • Sep 08
Invion Limited Announces PhotosoftTM Shows Activity Against Zika Virus in Preliminary Assays Invion Limited announced the positive screening results from in vitro studies of PhotosoftTM on the inhibition of the Zika virus. The results from the in vitro studies, which were undertaken by leading contract research and clinical laboratory service company Viroclinics-DDL and Virology Research Services Ltd, showed selected PhotosoftTM compounds to be effective against the virus and more efficacious than Monensin. Monensin is an antibiotic which is known to have activity against Zika in vitro laboratory tests and was used as a control (benchmark) in this study, but due to its in vivo toxicity cannot be used in humans. Zika virus is primarily transmitted by the Aedes Aegypti mosquito, which also transmits yellow fever and dengue. Symptoms associated with Zika include headache, skin rash and joint pain. Further, Zika has been linked to birth defects and other neurological complications. Invion holds the exclusive rights to the PhotosoftTM technology in Asia Pacific3 for the treatment of infectious diseases and atherosclerosis through its agreement with the technology licensor, RMW Cho Group Limited. Selected PhotosoftTM compounds demonstrated potent (over 99% inhibition) antiviral activity against Zika when exposed to specific light wavelengths. In addition to the potent activity of several PhotosoftTM compounds, low levels of cytotoxicity were observed. When assessed in combination, a resulting therapeutic index4 is calculated, which is a quantitative measurement of the potential efficacy relative to safety of the compound. Selected PhotosoftTM compounds were found to have a therapeutic index over 190 times higher than the control, Monensin. A recent report by CSIRO titled "Strengthening Australia's Pandemic Preparedness" identified the development of novel antivirals as a key science and technology area for strengthening Australia's pandemic preparedness. In vitro susceptibility of viruses to an antiviral agent was assessed using a quantitative assay to measure virus replication in the presence of increasing concentrations of the product (PhotosoftTM compounds) and a control compound (Monensin) compared to replication in the absence of the product. The primary screening assay utilised in this compound screening program was an immunofluorescence-based assay against Zika Strain MP1751 (African lineage) obtained from the contracted organisation, using the Vero E6 cell line. Compounds were serially diluted (8 concentrations) in a 96-well plate and added to the cells. Zika was then added, exposed to a specific light wavelength (660nm), and plates incubated for 48 hours . Additionally, compounds were assessed for cellular toxicity in Vero E6 cells. At the conclusion of incubation, infected cells were identified and counted via microscopy; lower percentages of stained cells compared to an untreated control represented cell protection from virus infection. Half maximal effective concentration (EC50) and half maximal cytotoxic concentration (CC50) were calculated by linear regression. Reported Earnings • Aug 19
Full year 2022 earnings released: EPS: AU$0 (vs AU$0 in FY 2021) Full year 2022 results: EPS: AU$0 (vs AU$0 in FY 2021). Revenue: AU$3.29m (up 41% from FY 2021). Net loss: AU$2.24m (loss widened 51% from FY 2021). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. お知らせ • Jun 09
Invion Limited Announces International Patent to Extend IP Protection for Photosoft Invion Limited announced that an International Patent Application, which includes the lead compound INV043, has been published. This patent builds upon previously granted PhotosoftTM related patents in Australia and other territories that Invion has exclusive rights to. The new patent, upon approval, will extend the global intellectual property (IP) protection for the PhotosoftTM technology for another two decades (the original patents are set to expire in 2033). Pre-clinical proof of concept studies of INV043, which is covered by this patent, conducted by Hudson Institute of Medical Research found: INV043 to be effective at ablating multiple types of cancer including triple negative breast cancer (TNBC), pancreatic and T-cell lymphoma Complete regression of established TNBC tumours in mice and provide protective immunity against recurrence of disease following treatment with INV043 Significant improvement in the effectiveness of immune checkpoint inhibitors (ICI), an established type of immunotherapy used in cancer treatment, when used in combination with a restricted administration of INV043. The patent application comes at an important juncture for Invion as the Company is preparing to undertake clinical trials using INV043 to treat cancers and opens up opportunities to combine INV043 with other established cancer therapies to improve patient outcomes. The new patent broadens commercial opportunities for Invion that include both: · Development of INV043 as a standalone therapy, and · Opens partnership opportunities with international pharmaceutical companies to develop combination therapies, such as INV043 and ICI's, potentially broadening the patient population who can benefit from such treatments. The newly filed patent covering clinical drug candidate INV043 has now progressed to the international examination phase. The application was filed by licensor and funder, RMW Cho Group Limited, pursuant to the Patent Cooperation Treaty (PCT), as the next phase in obtaining new patents in markets globally, including Australia and other territories that Invion has exclusive commercialising rights to. The findings of the International Search Report and associated Written Opinion from the European Patent Office considered the claims relating to INV043 as novel, inventive and meet the requirements for industrial applicability. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Non-Executive Director Alistair Bennallack was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. お知らせ • Feb 25
Invion Limited, Annual General Meeting, Mar 29, 2022 Invion Limited, Annual General Meeting, Mar 29, 2022, at 12:00 AUS Eastern Standard Time. Agenda: To acquire a license and distribution rights to Next Generation Photodynamic Therapy from RMW Cho Group Limited; to ratify prior issue of placement shares; to ratify placement options; to ratify SPP options; and to ratify broker options. Reported Earnings • Feb 24
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: EPS: AU$0 (vs AU$0 in 1H 2021). Revenue: AU$1.30m (up 4.4% from 1H 2021). Net loss: AU$1.05m (loss widened 23% from 1H 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) were also in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. お知らせ • Jun 04
Invion Limited announced that it expects to receive AUD 4.5 million in funding Invion Limited (ASX:IVX) announced a private placement of 321,428,571 ordinary fully paid shares at a price of AUD 0.014 per share for gross proceeds of AUD 4,500,000 on June 2, 2021. The transaction will include participation from RMW Cho Health Technology Limited. お知らせ • May 25
Invion Limited Announces Initial Proof-Of-Concept Results Show INV043 to Be Effective Invion Limited announced initial proof-of-concept testing results on INV043, the latest Active Pharmaceutical Ingredient using the PhotosoftTM technology. These proof-of-concept tests were undertaken in collaboration with Invion's research partner, the Hudson Institute of Medical Research (Hudson Institute), on a number of cancer types. The key findings from the studies are summarised below: Promising preliminary results that may have application across a range of cancers; INV043 has ~50 times greater phototoxicity than Invion's previous API (IVX-P03) and 600 times greater than Talaporfin sodium (widely used photosensitiser); Studies showed INV043 is selectively retained in malignant but not healthy tissues. Furthermore, no toxicity issues were identified up to 50x the therapeutic dose; Significant regression was observed in vivo in T-cell lymphoma, triple negative breast and pancreatic cancer models; INV043 also displayed fluorescence characteristics under blue light, which illuminated tumour growths. お知らせ • Apr 27
Invion Limited Announces Selection of New Active Pharmaceutical Ingredient to Progress with Invion Limited announced that following extensive research and development (R&D) efforts, it has selected a new Active Pharmaceutical Ingredient (API) to progress with. Provisional patents relating to the new API, called INV-043, have been filed and initial tests carried out by Invion's research partner, the Hudson Institute of Medical Research (Hudson Institute), indicate that INV-043 has greater anticancer activity and better cancer-targeting characteristics than previous generations of APIs developed by Invion. Hudson Institute is finalising work on initial proof-of-concept models testing ablation in three cancer types; triple negative breast cancer, T-cell lymphoma and pancreatic cancer, using immune deficient mice. Invion aims to finalise the findings in the coming weeks. Further, Hudson is commencing additional proof-of-concept work with INV-043 on immunocompetent in vivo models. The results from these proof-of-concept models will help shape Invion's R&D program, timelines and target indications. お知らせ • Sep 02
Invion Limited Auditor Raises 'Going Concern' Doubt Invion Limited filed its Annual on Aug 26, 2020 for the period ending Jun 30, 2020. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 